片子尺寸和重量对水基微波引起的 in situ 无形化的影响
Meng Zhang1, Korbinian Löbmann2, Gavin P Andrews1
1School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
International journal of pharmaceutics
|November 1, 2025
概括
微波诱导的现场无形化成功地产生了无形固体分散 (ASD) 在各种小型平板电脑大小用于儿科. 这种创新的药物输送方法提高了溶解率,并显示了个性化儿科配方的前景.
科学领域:
- 制药技术 制药技术 制药技术
- 材料科学 材料科学 材料科学
- 药物输送系统 药物输送系统
背景情况:
- 无形固体分散 (ASD) 提高了药物的溶解性和生物可用性,但在物理稳定性和加工方面面临挑战.
- 现有的微波诱导的现场无形化研究主要针对成人配方,忽视了儿科的需求.
- 儿科配方需要专门的方法,因为独特的患者考虑和较小的剂量要求.
研究的目的:
- 为了研究不同尺寸的迷你片对小儿药物配方微波诱导的现场无形化的影响.
- 建立一个新的平台,以使用in situ无形化来个性化儿童药物配方.
- 为了提高药物溶解率和儿童群体的患者遵守性.
主要方法:
- 使用微波诱导的现场无形化在6毫米,4毫米和2毫米的迷你片中制备印梅他辛 (IND) 和PVP/VA 64 ASD.
- 使用成像,结构和热分析对迷你平板电脑的表征.
- 在体外溶解测试和无形化程度的评估,包括2毫米迷你片的囊式配方.
主要成果:
- 在所有测试的迷你平板电脑尺寸 (低至2毫米) 中,实现了完整的无形化和改善的溶解率.
- 无论药片大小如何,都没有观察到溶解增强的显著差异.
- 视觉线索 (颜色变化) 和物理变化 (变形) 证实了无形化;2毫米迷你片的5合1配方显示了最高的无形化率.
结论:
- 微波诱导的现场无形化是一种可行的和可扩展的平台,用于创建改善药物溶解的儿科配方.
- 该技术可以应用于直径2毫米,重量4毫克的微型平板电脑.
- 这种方法为个性化儿科医学提供了一个有希望的策略,解决了稳定性和合规性问题.
相关概念视频
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
390
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
390
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.6K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.6K
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
658
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
658
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
296
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
296
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
142
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
142